Unraveling The Key Questions in EGFR-Driven NSCLC Treatment - Episode 6
EGFR mNSCLC: Future Directions
Panelists discuss how despite significant advances in EGFR-targeted therapy, critical unmet needs persist in EGFR-positive non–small cell lung cancer (NSCLC), including the need for better strategies to combat resistance mechanisms, more effective treatments for brain metastases, improved options for uncommon EGFR mutations, and the development of biomarker-driven approaches to optimize sequencing of available therapies.
Video Player is loading.
Video content above is prompted by the following:
- What is your perspective on the unmet needs in EGFR-positive NSCLC, and how could future trials address these